View More Recent Stories

Sep 9, 2024 11:56AM Goldman Sachs on Immunovant (IMVT): 'We view these data as compelling'
Sep 9, 2024 10:48AM Guggenheim on Immunovant (IMVT): 'we believe Graves' represents an underappreciated blockbuster commercial opp'y'
Sep 9, 2024 10:19AM Stifel on Immunovant (IMVT): 'upcoming data for Batoclimab in MG/CIDP (1Q25) remain important catalysts for the stock'
Sep 9, 2024 10:18AM Oppenheimer on Immunovant (IMVT): 'we see an attractive opportunity'
Sep 9, 2024 07:02AM Roivant Sciences (ROIV) Provides Update on Graves’ Disease Development Program
Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025
Aug 19, 2024 08:45AM Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT)
Jul 30, 2024 07:17AM RBC's biotech survey shows investors more bearish vs. last time
Mar 17, 2024 08:00PM Top pharma stocks to own in 2024 – Citi
View More Recent Stories